Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial.

OBJECTIVE: To study whether recombinant human erythropoietin (r-hu-Epo) improves anaemia and reduces disease activity in patients with rheumatoid arthritis and anaemia of chronic disease (ACD). METHODS: A 52 week placebo controlled randomised double blind trial with r-hu-Epo was performed in 70 pati...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Peeters, H R, Jongen-Lavrencic, M, Vreugdenhil, G, Swaak, A J
Format: Artigo
Jezik:Inglês
Izdano: 1996
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1010292/
https://ncbi.nlm.nih.gov/pubmed/8984939
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items